Warning
Novo Nordisk Inc. Recalls Wegovy (semaglutide) Injection
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0244-2026Drug / Pharmaceutical
Novo Nordisk Inc. Recalls Wegovy (semaglutide) Injection
Novo Nordisk Inc. · Class II — Moderate Risk
Product Description
Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4505-14
Reason for Recall
Presence of Particulate Matter: Hair was found in a prefilled syringe
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Nationwide within the United States.
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
The FDA classified this recall as Class II, indicating the pharmaceutical product may cause temporary health problems or poses a slight threat of a serious nature. Novo Nordisk Inc. initiated the recall on December 19, 2025. Presence of Particulate Matter: Hair was found in a prefilled syringe. The product was distributed nationwide. Consumers should check their purchases and discontinue use of any affected product. Contact Novo Nordisk Inc. for further instructions.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medical Product Contamination.